Home/Pipeline/Scemblix® (asciminib)

Scemblix® (asciminib)

Chronic Myeloid Leukemia (CML)

Approved / LifecycleActiveN/A

Key Facts

Indication
Chronic Myeloid Leukemia (CML)
Phase
Approved / Lifecycle
Status
Active
Company

About Novartis

Novartis is a global pharmaceutical leader with a mission to reimagine medicine to improve and extend lives. With a market cap of $290.10B, it operates across 118 countries, reaching over 300 million patients annually. Its strategy focuses on delivering high-value medicines for society's greatest disease burdens through technology leadership in R&D and novel access approaches, powered by a diversified portfolio across oncology, cardiovascular, immunology, neuroscience, and rare diseases.

View full company profile

Other Chronic Myeloid Leukemia (CML) Drugs

DrugCompanyPhase
XS003 (nilotinib)Xspray PharmaNDA Submitted
TERN-701Terns PharmaceuticalsPhase 3
ELVN-001Enliven TherapeuticsPhase 1b